Navigation Links
Industry Executives Finding Value in Shift of Scientific Publications
Date:5/16/2008

CHAPEL HILL, N.C., May 16 /PRNewswire/ -- The landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. Half of global publications groups are fully located in the marketing function, but publications leaders foresee a shift to medical groups to increase clinical presentation, according to a new report released by Best Practices, LLC.

In a benchmarking study that included such influential companies as Pfizer, GlaxoSmithKline, Lilly and Merck, it was found that 14 percent of participating pharmaceutical and biotech companies avoid using global or regional marketing representatives to develop their global publications strategy. These companies, which align publications strictly within the medical group, receive strategic input from medical directors, advisor physicians and biostatisticians.

For a complimentary summary of the full report "Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance," click on the following link http://www3.best-in-class.com/rr946.htm . The study guides pharmaceutical and biotechnology companies in the transition to the new publishing environment to create the desired synergy between credibility of scientific rigor and increased commercial success.

Other key topic areas in the research include:

-- Impact of transparency guidelines on publications, planning and

delivery

-- Tactics for handling publication of neutral or negative clinical trial

results

-- Optimal structure for the global publications function

-- Transition of global publication function from commercial to clinical

-- Strategy changes for the new marketplace

Among the key topics gathered in this report are:

-- Centralization of publications strategy, planning and delivery

-- Trends surrounding regional strategy contribution

-- Strategies for publishing neutral/negative results

-- Outsourcing of global publications resources

-- Measures used for performance evaluation

For more information on this report, contact Robert Naylor at rnaylor@best-in-class.com or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr946.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees
2. Genetic Testing for All: QTrait Offers Industrys Least Expensive, Most Secure DNA Tests With TRUSTe Certification
3. Veteran Drug Industry Executive to Become President of CTI
4. Startech Environmental to Have Three Plasma Converters in Former Pharmaceutical Industry Facility in Puerto Rico
5. Another industry first enabled by Benchmark Biolabs - Peros oral delivery platform and vaccine facility licensed by the USDA
6. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
7. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
8. Life Science Executive Exchange 2008 To Sponsor Industry Awards
9. Ohio Task Force Begins Mission of Creating a New 21st Century Industry
10. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
11. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, today announced financial results for the fiscal ... delivering on our commitment to address an unmet ... are pleased with the early clinical response data ... are focused on advancing our lead program – ...
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
Breaking Biology News(10 mins):